Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.50 |
| ▸ | FNTA | P49354 | 5/20 | 0.43 |
| ▸ | FNTB | P49356 | 5/20 | 0.43 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | VNN1 | O95497 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GPR6 | P46095 | 2/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3527236 | 0.93 | MAPK14 (0.45) | MAPK14FNTAFNTBVNN1GPR6 | |
| SCHEMBL3522226 | 0.91 | MAPK14 (0.51) | MAPK14FNTAFNTBKDM4EALDH1A1 | |
| SCHEMBL4380849 | 0.83 | MAPK14 (0.58) | MAPK14FNTAFNTBKDM4EALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL4489690 | 0.77 | MAPK14 (0.52) | MAPK14FNTAFNTBKDM4EALDH1A1 | |
| SCHEMBL3523357 | 0.76 | MAPK14 (0.43) | MAPK14POLB | |
| SCHEMBL3527823 | 0.75 | MAPK14 (0.53) | MAPK14 | |
| SCHEMBL3525647 | 0.75 | MAPK14 (0.71) | MAPK14FNTAFNTB | |
| SCHEMBL29594334 | 0.74 | MAPK14 (0.59) | MAPK14KDM4EALDH1A1HSD17B10VNN1 | |
| SCHEMBL4387481 | 0.74 | MAPK14 (0.59) | MAPK14KDM4EALDH1A1HSD17B10VNN1 | |
| SCHEMBL13686775 | 0.73 | FNTA (0.54) | MAPK14FNTAFNTBDCTPP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795271-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | PFIZER INC | 2009-12-10 | — | — | US | disclosed |
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | PHARMACIA CORPORATION (US) | 2007-07-19 | — | — | US | disclosed |
| US-7183287-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2007-02-27 | — | — | US | disclosed |
| US-20040242608-A1 | Substituted pyrimidinones | PHARMACIA LLC | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | MAPK1, MAP3K8, MAP3K7 | MAPK14 38/4885FNTA 3560/4885FNTB 3509/4885 |
| US-20040242608-A1 | Substituted pyrimidinones | MAPK1, MAPK7, MAP3K8 | MAPK14 29/4885FNTA 3035/4885FNTB 2766/4885 |
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | MAPK1, MAP3K8, MAP3K7 | MAPK14 38/4885FNTA 3560/4885FNTB 3509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.